Celltrion’s Vegzelma Becomes Fourth US-Approved Bevacizumab
Estimated US Market Launch Date Is H1 2023
Executive Summary
Celltrion’s Vegzelma earns a long-awaited USFDA approval. The oncology biosimilar will be up against established bevacizumab products from Amgen and Pfizer as well as recent newcomer Amneal.
You may also be interested in...
Celltrion To Jostle For Space In Crowded EU Bevacizumab Market
The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the critical late-stage cancer treatment.
Celltrion Sees ‘Record-High Revenue’ With Increasing Infliximab Sales
South Korea’s Celltrion has delivered a strong fourth quarter in FY21 based on the increase in infliximab sales across all markets as well as a contribution from its Regkirona COVID-19 treatment. The company expects modest top-line growth to continue by launching at least one biological product every year.
Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab
Celltrion has indicated that it intends to leverage its ability to compete on cost to gain a foothold in the bevacizumab market, despite being a “latecomer” in the wake of firms that have previously launched and filed biosimilar rivals to Avastin.